Clinical trial
A First-in-human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered YN001 in Healthy Subjects
NCT05635084 is registered in ClinicalTrials.gov with Beijing Inno Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First-in-human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered YN001 in Healthy Subjects
- Lead sponsor
- Beijing Inno Medicine Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 16, 2022
- Completion date
- August 9, 2024
- Enrollment
- 64 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.